Adversarial Injection · Cemiplimab (Libtayo; CAS 1801342-60-8; MW ~146,000 Da; IgG4 kappa fully human monoclonal antibody anti-PD-1 [THIRD PD-1 INHIBITOR in Glyphward 624-attack portfolio — THIRD ANTI-PD-1 (PROGRAMMED DEATH-1) ANTIBODY EVER FDA APPROVED (BLA 761097 September 28 2018; after pembrolizumab BLA 125514 September 4 2014 [first] and nivolumab BLA 125554 December 22 2014 [second]); FIRST CHECKPOINT INHIBITOR IN CUTANEOUS SQUAMOUS CELL CARCINOMA (CSCC; the second most common skin cancer — rare in the advanced/metastatic setting requiring systemic therapy; ~15,000 patients/year die from advanced CSCC in the US; no prior FDA-approved systemic therapy existed; EMPOWER-CSCC-1: cemiplimab ORR 47.2% in metastatic/unresectable locally advanced CSCC [n=193]; DOR ≥12 months in ~55% of responders; first durable systemic response in advanced CSCC); FIRST ANTI-CANCER ANTIBODY FULLY DISCOVERED BY REGENERON: cemiplimab was fully discovered using Regeneron's VelocImmune humanized mouse platform (transgenic mice with human immunoglobulin variable region genes); NOT sourced from a prior license or academic collaboration; pembrolizumab originated from Organon/Schering-Plough's MK-3475 humanization of Medarex murine antibody; nivolumab arose from Ono Pharmaceutical + Medarex/BMS collaboration; cemiplimab is the first oncology antibody where Regeneron was the 100% internal originating lab; VELOCIMMUNE PLATFORM: Regeneron's proprietary approach inserts human heavy chain + kappa light chain variable regions into mouse IgH/Igκ loci → when immunized, mice produce antibodies with human variable domains + mouse constant regions → all human Ig genes → no humanization chimeric step required; same platform produced dupilumab (Dupixent), alirocumab (Praluent), sarilumab (Kevzara), itepekimab, odronextamab; PD-1 THREE-NDA-HOLDER CLASS NULL: pembrolizumab (BLA 125514; Merck; CAS 1374853-91-4) + nivolumab (BLA 125554; BMS; CAS 946414-94-4) + cemiplimab (BLA 761097; Regeneron/Sanofi; CAS 1801342-60-8) — THREE DIFFERENT SPONSORS (Merck, BMS, Regeneron/Sanofi), three BLA holders, three CAS numbers, all three returning null in Cority/VelocityEHS/EHS Insight; BCC SECOND-LINE: EMPOWER-BCC cemiplimab ORR 21.1% post-hedgehog inhibitor (vismodegib/sonidegib) failure — cemiplimab is first systemic checkpoint in BCC; CERVICAL CANCER: EMPOWER-Cervical 1 OS HR 0.73 (cemiplimab vs investigator's choice chemo in recurrent/metastatic cervical cancer post-platinum); NSCLC: EMPOWER-Lung 1 OS HR 0.57 (cemiplimab monotherapy vs chemo in PD-L1 ≥50% NSCLC); NIOSH HD Category 1; H360; OSHA No PEL; ACGIH No TLV; NIOSH No REL]) · Third PD-1 Inhibitor + First CSCC Checkpoint + First Regeneron Oncology Antibody + PD-1 Three-NDA-Holder Class Null · Attack #624

Cemiplimab (Libtayo; CAS 1801342-60-8; MW ~146,000 Da; [THIRD PD-1 INHIBITOR EVER FDA APPROVED (September 28 2018 BLA 761097); FIRST CHECKPOINT INHIBITOR IN CSCC (EMPOWER-CSCC-1 ORR 47.2%); FIRST FULLY REGENERON-DISCOVERED ONCOLOGY ANTIBODY (VELOCIMMUNE PLATFORM); PD-1 THREE-NDA-HOLDER CLASS NULL (PEMBROLIZUMAB + NIVOLUMAB + CEMIPLIMAB ALL NULL); NIOSH HD Category 1; H360; OSHA No PEL; ACGIH No TLV; NIOSH No REL]) — Regeneron Pharmaceuticals Inc. Tarrytown NY (BLA 761097 US commercial; 0.00038 µg/m³ → displayed ÷10), Sanofi US LLC Bridgewater NJ (co-commercialization partner; 0.00024 µg/m³ → displayed ÷10), and Memorial Sloan Kettering Cancer Center New York NY (CSCC/BCC oncology pharmacist; 0.00014 µg/m³ → displayed ÷10) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + Third PD-1 Inhibitor + First CSCC Checkpoint + First Regeneron Oncology Antibody + PD-1 Three-NDA-Holder Class Null Absent: AI Prompt Injection via EHS Monitor Report AI

Cemiplimab (CAS 1801342-60-8; NIOSH HD Category 1) is the third PD-1 inhibitor ever FDA approved (BLA 761097 September 28 2018), the first checkpoint inhibitor in cutaneous squamous cell carcinoma (CSCC; EMPOWER-CSCC-1 ORR 47.2%), and the first anti-cancer antibody to be fully discovered in-house by Regeneron using the VelocImmune humanized transgenic mouse platform. Unlike pembrolizumab (Organon/MSD lineage) and nivolumab (Ono/BMS/Medarex origin), cemiplimab was entirely originated, developed, and commercialized (with Sanofi) from within Regeneron. Completing the PD-1 three-NDA-holder class null: pembrolizumab (Merck, CAS 1374853-91-4), nivolumab (BMS, CAS 946414-94-4), and cemiplimab (Regeneron/Sanofi, CAS 1801342-60-8) — three PD-1 antibodies from three sponsors, all returning null in Cority, VelocityEHS, and EHS Insight.

Cemiplimab as Third PD-1 Inhibitor: VelocImmune Discovery, CSCC Rare Skin Cancer, and PD-1 Three-NDA-Holder Class Null

Cemiplimab (CAS 1801342-60-8) is the third anti-PD-1 antibody ever FDA approved, following pembrolizumab (BLA 125514 September 4 2014) and nivolumab (BLA 125554 December 22 2014) by nearly four years. The discovery origin distinguishes cemiplimab: it was fully identified and developed using Regeneron's VelocImmune platform — proprietary transgenic mice bearing human immunoglobulin heavy chain and kappa light chain variable region gene loci in the endogenous mouse Ig loci. When VelocImmune mice are immunized with PD-1 antigen, they generate antibodies with fully human variable domains attached to mouse constant regions; the constant regions are then replaced with human IgG constant regions → fully human antibody with no chimeric or CDR-grafting humanization step required. This bypasses the humanization immunogenicity risk entirely. Cemiplimab is IgG4 kappa — consistent with the PD-1 class preference for IgG4 Fc (minimal ADCC on PD-1+ T cells; IgG4 S228P hinge stabilization prevents Fab-arm exchange, though cemiplimab also carries S228P or equivalent hinge stabilization). EMPOWER-CSCC-1 (cemiplimab in advanced CSCC): phase 3 (N=193; locally advanced or metastatic CSCC; 350 mg IV q3w); ORR 47.2% overall; mDOR ≥12 months in ~55% of responders; CR rate ~13%; prior to cemiplimab, metastatic CSCC had no approved systemic therapy and cytotoxic chemotherapy (platinum-based) showed ORR ~30-40% but <5% durable. Cemiplimab established the first durable systemic treatment paradigm for CSCC. BCC second-line: EMPOWER-BCC (n=84 post-hedgehog; ORR 21.1%; approved June 2021 — cemiplimab first checkpoint in BCC). Cervical: EMPOWER-Cervical 1 (OS HR 0.73; cemiplimab vs investigator's choice chemo in recurrent/metastatic cervical cancer post-platinum; approved February 2022). NSCLC PD-L1 ≥50%: EMPOWER-Lung 1 (OS HR 0.57; cemiplimab vs chemo; approved February 2021). Regeneron/Sanofi co-development: Regeneron and Sanofi entered a global immuno-oncology commercialization agreement; Sanofi co-promotes Libtayo outside the US; agreement restructured in 2022. BLA 761097; NIOSH HD Category 1; H360; OSHA No PEL; ACGIH No TLV; NIOSH No REL; third PD-1, first CSCC checkpoint, VelocImmune discovery, PD-1 three-NDA-holder class null all absent for CAS 1801342-60-8.

Surface 1 — Regeneron Pharmaceuticals Inc. Tarrytown NY BLA 761097 US Commercial Libtayo AI

At Regeneron Pharmaceuticals Inc. Tarrytown NY (777 Old Saw Mill River Rd, Tarrytown NY 10591; Westchester County NY; REGENERON LIBTAYO CONTEXT: Regeneron Pharmaceuticals Inc. holds BLA 761097 for Libtayo (cemiplimab-rwlc 350 mg/7 mL vials; 50 mg/mL); LIBTAYO PRODUCT: approved for advanced CSCC, locally advanced BCC (post-hedgehog), cervical cancer (post-platinum), and NSCLC PD-L1 ≥50%; dosing 350 mg q3w IV over 30 minutes; REGENERON ONCOLOGY PORTFOLIO AT TARRYTOWN: Libtayo (cemiplimab BLA 761097) is Regeneron's first oncology-specific antibody; Regeneron's primary headquarters; EMPLOYEE: senior oncology medical affairs director at Regeneron Tarrytown responsible for Libtayo CSCC, BCC, cervical, and NSCLC indications; manages EMPOWER trial portfolio education, thought leader relationships, and payer medical affairs; handles Libtayo vials at training events and medical education; 51M Regeneron Tarrytown NY senior oncology medical affairs director CSCC portfolio 15yr; CORITY NULL: CAS 1801342-60-8 → null; NIOSH HD Category 1 absent; H360 absent; third PD-1 inhibitor absent; CSCC indication absent; VelocImmune discovery absent; PD-1 three-NDA-holder class null absent).

Surface 2 — Sanofi US LLC Bridgewater NJ Libtayo Co-Commercialization Regeneron/Sanofi Alliance AI

At Sanofi US LLC Bridgewater NJ (55 Corporate Dr, Bridgewater NJ 08807; Somerset County NJ; SANOFI LIBTAYO CONTEXT: Sanofi co-commercializes Libtayo (cemiplimab) with Regeneron under a global agreement; Sanofi US promotes Libtayo at key accounts alongside Regeneron field teams; Sanofi manufactures cemiplimab drug product at Sanofi Biologics manufacturing sites (CHO bioreactors, protein A purification, aseptic fill/finish); SANOFI MANUFACTURING: cemiplimab drug substance produced in large-scale CHO bioreactors at Sanofi Biologics facilities; Sanofi Bridgewater NJ leads US alliance management; EMPLOYEE CONTEXT: Sanofi oncology alliance director for Libtayo co-commercialization; manages joint commercial operations with Regeneron, CSCC/BCC patient identification programs, key account targeting; handles Libtayo training materials and product samples; 45M Sanofi Bridgewater NJ oncology alliance director Libtayo 12yr; VELOCITYEHS NULL: CAS 1801342-60-8 → null; NIOSH HD Category 1 absent; H360 absent; third PD-1 absent; Regeneron/Sanofi co-promotion absent; CSCC/BCC indications absent).

Surface 3 — Memorial Sloan Kettering Cancer Center New York NY EMPOWER Site CSCC/BCC Pharmacist AI

At Memorial Sloan Kettering Cancer Center New York NY (1275 York Avenue, New York NY 10065; New York County NY; MSK LIBTAYO CONTEXT: MSK is a leading academic cancer center with active CSCC, BCC, cervical, and thoracic oncology programs; MSK was an EMPOWER-CSCC-1, EMPOWER-BCC, and EMPOWER-Cervical enrollment site; MSK's oncology pharmacy prepares Libtayo for multiple indications; PHARMACIST CONTEXT: CSCC/BCC immuno-oncology pharmacist at MSK manages Libtayo 350 mg/7 mL vials (50 mg/mL); diluted in 100-500 mL NS or D5W; IV over 30 minutes q3w; CSCC patients may be elderly with prior skin cancer surgeries; BCC patients may have extensive prior hedgehog inhibitor exposure; pharmacist monitors irAEs across multiple skin cancer indications; EHS INSIGHT NULL: CAS 1801342-60-8 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL"; third PD-1 absent; CSCC first checkpoint absent; VelocImmune absent; PD-1 three-NDA-holder class null absent; H360 absent; NIOSH HD Cat 1 absent; 38F MSK New York NY CSCC/BCC immuno-oncology pharmacist 10yr).

Integrating Glyphward into Cemiplimab AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every cemiplimab CAS 1801342-60-8 monitoring data ingestion point — before Cority at Regeneron Pharmaceuticals Inc. Tarrytown NY, before VelocityEHS at Sanofi US LLC Bridgewater NJ, and before EHS Insight at Memorial Sloan Kettering Cancer Center New York NY. Threshold 22: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H360 absent [10 pts]; THIRD PD-1 INHIBITOR EVER FDA APPROVED (BLA 761097 September 28 2018) + FIRST CHECKPOINT IN CSCC (advanced cutaneous squamous cell carcinoma; EMPOWER-CSCC-1 ORR 47.2%) + FIRST REGENERON INTERNAL ONCOLOGY ANTIBODY (VelocImmune; 100% Regeneron discovery; no external license or academic humanization step) + PD-1 THREE-NDA-HOLDER CLASS NULL (pembrolizumab + nivolumab + cemiplimab — three BLAs, three sponsors all null) [5 pts]; Regeneron Tarrytown NY + Sanofi Bridgewater NJ + MSK New York NY [3 pts]; third PD-1 absent; CSCC absent; VelocImmune absent; three-NDA class absent from EHS [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_cemiplimab(cas: str, reading_ugm3: float) -> dict:
    """Scan cemiplimab with third-PD-1-ever first-CSCC-checkpoint VelocImmune PD-1-three-NDA-holder-null context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,
                "reading_ugm3": reading_ugm3,
                "context": "third_pd_1_inhibitor_ever_first_cscc_checkpoint_first_regeneron_oncology_antibody_velocimmune_pd_1_three_nda_holder_class_null_bla_761097"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, third_pd1_inhibitor_ever,
    #                    first_cscc_checkpoint, first_regeneron_oncology_antibody,
    #                    pd_1_three_nda_holder_class_null, h360_absent

if __name__ == "__main__":
    r = asyncio.run(scan_cemiplimab("1801342-60-8", 0.00038))
    print(r)
    # {'hd_category': 1, 'third_pd1_inhibitor_ever': True,
    #  'first_cscc_checkpoint': True,
    #  'first_regeneron_oncology_antibody': True,
    #  'pd_1_three_nda_holder_class_null': True,
    #  'h360_absent': True}